ReviewThe lancet. HIV2021
A tale of four studies: HIV vaccine immunogenicity and efficacy in clinical trials.
Review in The lancet. HIV, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Trial
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Rapid and robust immune response boosting with potent, next-generation adjuvant in viral vector-primed primates.Journal of virology · 2026Article
- Full-length next-generation sequencing of 11 HLA loci of more than 1000 individuals from clinical cohorts in East and West Africa.bioRxiv : the preprint server for biology · 2025Article
- Review
- The Question of HIV Vaccine: Why Is a Solution Not Yet Available?Journal of immunology research · 2024Review
- HIV infection.Nature reviews. Disease primers · 2023Review
- Structures and immune recognition of Env trimers from two Asia prevalent HIV-1 CRFs.Nature communications · 2023Article
- Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.PLoS pathogens · 2023Article
- Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission.Current HIV/AIDS reports · 2022Review
- Natural Immunity against HIV-1: Progression of Understanding after Association Studies.Viruses · 2022Review
- Reappraising the Value of HIV-1 Vaccine Correlates of Protection Analyses.Journal of virology · 2022Review
- Safety and Efficacy of the Common Vaccines against COVID-19.Vaccines · 2022Review
- Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.Nature communications · 2022Article
- Current Status of HIV-1 Vaccines.Vaccines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The advanced-phase HIV prevention vaccine trials done in South Africa (HVTN 702) and in Thailand (RV144), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results. The South African trial did not find vaccine efficacy, whereas the Thai trial had modest, but statistically significant, success with the modified intention-to-treat analysis prespecified in the protocols of both studies. An understanding of the differences between the studies is required to avoid the possible, but erroneous, conclusion that the results from the South African trial negatively affect the results of the Thai trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.